Tumor Biology

, Volume 35, Issue 3, pp 1785–1790 | Cite as

CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis

  • Yan Zhang
  • Shengchun Tong
  • Lihua Guan
  • Fei Na
  • Wei Zhao
  • Li Wei
Research Article


CD95 is the first death receptor identified and characterized in recent years, and it plays important roles in the molecular network regulating cell death and survival. CD95 rs1800682 polymorphism is a common genetic polymorphism identified in the CD95 gene. Many publications evaluated the association between CD95 rs1800682 polymorphism and cervical cancer risk, but the association remained inconclusive. To provide a more precise estimate on the association, a meta-analysis was carried out. The association between CD95 rs1800682 polymorphism and cervical cancer risk was assessed by calculating the pooled odds ratio (OR) with its 95 % confidence intervals (95 % CI). On the basis of our inclusion criteria, ten studies with a total of 5,481 individuals were included into the meta-analysis. There was obvious heterogeneity among the included studies. Meta-analysis of the ten studies suggested that there was no association between CD95 rs1800682 polymorphism and cervical cancer risk under all four genetic models (allele model: OR = 1.05, 95 % CI 0.92–1.18, P = 0.478; homozygous model: OR = 1.08, 95 % CI 0.83–1.41, P = 0.550; dominant model: OR = 1.12, 95 % CI 0.88–1.42, P = 0.347; recessive model: OR = 1.00, 95 % CI 0.76–1.31, P = 0.978). Subgroup analysis by ethnicity suggested that there was no association between CD95 rs1800682 polymorphism and cervical cancer risk in Asians, Caucasians, and Africans. Thus, the meta-analysis suggests that CD95 rs1800682 polymorphism is not associated with cervical cancer risk.


CD95 Cervical cancer Association Meta-analysis 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.PubMedCrossRefGoogle Scholar
  4. 4.
    Ibeanu OA. Molecular pathogenesis of cervical cancer. Cancer Biol Ther. 2011;11:295–306.PubMedCrossRefGoogle Scholar
  5. 5.
    Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem. 2002;48:1218–24.PubMedGoogle Scholar
  6. 6.
    de Freitas AC, Gurgel AP, Chagas BS, Coimbra EC, do Amaral CM. Susceptibility to cervical cancer: an overview. Gynecol Oncol. 2012;126:304–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaabane W, User SD, El-Gazzah M, Jaksik R, Sajjadi E, Rzeszowska-Wolny J, et al. Autophagy, apoptosis, mitoptosis and necrosis: interdependence between those pathways and effects on cancer. Arch Immunol Ther Exp (Warsz). 2013;61:43–58.CrossRefGoogle Scholar
  8. 8.
    Schutze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol. 2008;9:655–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Steller EJ, Borel Rinkes IH, Kranenburg O. How CD95 stimulates invasion. Cell Cycle. 2011;10:3857–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Tauzin S, Debure L, Moreau JF, Legembre P. CD95-mediated cell signaling in cancer: mutations and post-translational modulations. Cell Mol Life Sci. 2012;69:1261–77.PubMedCrossRefGoogle Scholar
  11. 11.
    Yurchenko M, Shlapatska LM, Sidorenko SP. The multilevel regulation of CD95 signaling outcome. Exp Oncol. 2012;34:153–9.PubMedGoogle Scholar
  12. 12.
    Ueda M, Toji E, Nunobiki O, Izuma S, Okamoto Y, Torii K, et al. Germline polymorphism of cancer susceptibility genes in gynecologic cancer. Hum Cell. 2008;21:95–104.PubMedCrossRefGoogle Scholar
  13. 13.
    Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer. 2003;103:221–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Zoodsma M, Nolte IM, Schipper M, Oosterom E, van der Steege G, de Vries EG, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer. 2005;15 Suppl 3:282–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, et al. Fas gene promoter-670 polymorphism in gynecological cancer. Int J Gynecol Cancer. 2006;16 Suppl 1:179–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Kang S, Dong SM, Seo SS, Kim JW, Park SY. Fas-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet. 2008;180:1–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Kordi Tamandani DM, Sobti RC, Shekari M. Association of Fas-670 gene polymorphism with risk of cervical cancer in north Indian population. Clin Exp Obstet Gynecol. 2008;35:183–6.PubMedGoogle Scholar
  18. 18.
    Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, et al. Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among black and mixed-ancestry South Africans. BMC Res Notes. 2009;2:238.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Zucchi F, da Silva ID, Ribalta JC, de Souza NC, Speck NM, Girao MJ, et al. Fas/CD95 promoter polymorphism gene and its relationship with cervical carcinoma. Eur J Gynaecol Oncol. 2009;30:142–4.PubMedGoogle Scholar
  20. 20.
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRefGoogle Scholar
  21. 21.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  23. 23.
    Chen Y, Lv W, Qian Q, Ye F. Fas-670 single nucleotide polymorphisms and susceptibility to cervical cancer. Natl Med J China. 2006;86:2792–4.Google Scholar
  24. 24.
    Li H, Guo HY, Sun T, Zhou YF, Lin DX, Zhang WH, et al. Association between Fas/Fas L genes promoter polymorphisms and pathogenic risk of cervical cancer. Zhonghua Zhong Liu Za Zhi. 2009;31:38–41.PubMedGoogle Scholar
  25. 25.
    Zhang Z, Qiu L, Wang M, Tong N, Li J. The FAS ligand promoter polymorphism, rs763110 (−844C > T), contributes to cancer susceptibility: evidence from 19 case–control studies. Eur J Hum Genet. 2009;17:1294–303.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Wu Z, Wang H, Chu X, Chen J, Fang S. Association between FAS-1377 G/A polymorphism and susceptibility to gastric cancer: evidence from a meta-analysis. Tumour Biol. 2013;34:2147–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Wu CY, Yang M, Lin M, Li LP, Wen XZ. MTHFR C677T polymorphism was an ethnicity-dependent risk factor for cervical cancer development: evidence based on a meta-analysis. Arch Gynecol Obstet. 2013;288:595–605.PubMedCrossRefGoogle Scholar
  28. 28.
    Zhang HL, Zhang YJ. A systemic assessment of the association between tumor necrosis factor alpha 308 G/A polymorphism and risk of cervical cancer. Tumour Biol. 2013;34:1659–65.PubMedCrossRefGoogle Scholar
  29. 29.
    Sui Y, Han W, Yang Z, Jiang M, Li J. Association of glutathione S-transferase M1 and T1 null polymorphisms with the development of cervical lesions: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011;159:443–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Ni J, Ye Y, Teng F, Wu Q. Interleukin 10 polymorphisms and cervical cancer risk: a meta-analysis. Int J Gynecol Cancer. 2013;23:126–33.PubMedCrossRefGoogle Scholar
  31. 31.
    Li F, Liu Y, Fu T, Tong W, Zhang A. Associations of three common polymorphisms in CD95 and CD95L promoter regions with gastric cancer risk. Tumour Biol. 2013;34:2293–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhang Z, Xue H, Gong W, Wang M, Yuan L, Han S, et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case–control studies. Carcinogenesis. 2009;30:487–93.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Yan Zhang
    • 1
  • Shengchun Tong
    • 1
  • Lihua Guan
    • 1
  • Fei Na
    • 1
  • Wei Zhao
    • 1
  • Li Wei
    • 1
  1. 1.Department of GynecologyThe Fourth Hospital Affiliated to China Medical UniversityShenyangChina

Personalised recommendations